To Study The Molecular Characterization Of Extended Spectrum Β-Lactamase (ESBL) Producing E.COLI Isolates With Its Antibiotic Resistance Profile to Blactx and Blashv Gene From Patients of Urinary Tract Infections
Keywords:
ESBL, Urinary Tract Infection, MDR, β-Lactams, CLSIAbstract
Introduction: Health care-associated urinary tract infections (HAUTIs) are common and contribute to severe morbidity and high fatality rate in hospitalized patients. About 80% of HAUTIs occur in patients who undergo instrumentation of the urinary tract including catheter-associated urinary tract infections. The emergence of extended-spectrum β-lactamase (ESBL) is frequently associated with prolonged hospital stay, increased treatment cost, and limited treatment options especially wide-spectrum antibiotics. However, due to their widespread and mostly inappropriate usage, resistance to these medications has significantly grown, particularly as a result of the creation of extended-spectrum β-lactamase (ESBL).
Aim and Objective: To study the molecular characterization of extended spectrum β-lactamase (ESBL) producing E.coli isolates with associated gene to blaCTX and blaSHV gene from patients of urinary tract infections.
Material and Methods: This was a Cross sectional study carried out in the department of Microbiology for a period of 12 months i.e, September 2023 to September 2024. A total of 366 E. coli isolates of all the Uropathogenic E. coli strain which were isolated from urine samples were collected from hospitalized and consultation patients in the study. The Antimicrobial susceptibility testing was performed according to the CLSI guidelines 2024. The DNA extraction was performed using the Qiagen DNA extraction kit and the gene blaCTX and blaSHV was detected using the PCR.
Results: In the present study out of the 1012 isolates there were 366 (36.1%) which showed the growth of E. coli. In which 82 (22.5%) were phenotypically identified as ESBL producers and 284 (77.6%) were Non-ESBL. Out of the 366 isolates, 110 (30%) were Males and 256 (69.9%) were Females patients. The overall susceptibility of ESBL isolates to various antibiotics was as Ampicillin (17.20%), Ampicillin/Sulbactam (28.5%), Gentamycin (65.7%), Cefoxitin (51.0%), Amikacin (80%), Ciprofloxacin (48%), Meropenem (97.2%), Ceftazidime(0%), Ceftazidime/ clavunalate(100%), Piperacillin/tazobactam (85.7%), Ceftriaxone(0%), Nitrofurantoin(100%), Tigecycillin(97.2%) and fosfomycin(97.2%). In the current study out of the total 82 isolates there were 25 (30.4%) were observed positive for blaCTX gene and 11 (13.4%) observed positive for blaSHV gene.
Conclusion: There are now fewer treatment choices and increased medical costs as a result of the substantial expansion of E. coli that produces ESBL. Trends for regional epidemiological data on antimicrobial resistance must be updated to support appropriate antibiotic administration, effective infection control, and clinical care management.
Downloads
References
Abuoun, M., O'connor, H. M., Stubberfield, E. J., Nunez-Garcia, J., Sayers, E., Crook, D. W., et al. Characterizing antimicrobial resistant Escherichia coli and associated risk factors in a cross-sectional study of pig farms in Great Britain. Front. Microbiol. 2020; 11:861.
Anjum, M. F., Marco-Jimenez, F., Duncan, D., Marín, C., Smith, R. P., and Evans, S. J. Livestock-associated methicillin-resistant Staphylococcus aureus from animals and animal products in the UK. Front. Microbiol. 2019; 10, 2136.
Kózka M, Sega A, Wojnar-Gruszka K, Tarnawska A, Gniadek A. Risk factors of pneumonia associated with mechanical ventilation. Int J Environ Res Public Health. 2020; 17(2):656.
Anjum, M. F., Schmitt, H., Börjesson, S., and Berendonk, T. U. The potential of using E. coli as an indicator for the surveillance of antimicrobial resistance (AMR) in the environment. Curr. Opin. Microbiol. 2021; 64, 152–158.
Lindblom A, Kiszakiewicz C, Kristiansson E, Yazdanshenas S, Kamenska N, Karami N, Åhrén C. The impact of the ST131 clone on recurrent ESBL-producing E. coli urinary tract infection: a prospective comparative study. Sci Rep. 2022; 12(1):10048.
Muller A, Gbaguidi-Haore H, Cholley P, Hocquet D, Sauget M, Bertrand X. Hospital-diagnosed infections with Escherichia coli clonal group ST131 are mostly acquired in the community. Sci Rep. 2021; 11(1):5702.
Mahazu S, Sato W, Ayibieke A, Prah I, Hayashi T, Suzuki T, Iwanaga S, Ablordey A, Saito R. Insights and genetic features of extended-spectrum beta-lactamase producing Escherichia coli isolates from two hospitals in Ghana. Sci Rep. 2022; 12(1):1843.
Bennani, H., Mateus, A., Mays, N., Eastmure, E., Stärk, K. D. C., and Häsler, B. (2020). Overview of evidence of antimicrobial use and antimicrobial resistance in the food chain. Antibiotics. 2020; 9:49.
Reynolds D, Burnham JP, Vazquez Guillamet C, McCabe M, Yuenger V, Betthauser K, Micek ST, Kollef MH. The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic. Eur Respir Rev. 2022; 31(166):220068.
Duggett, N., Ellington, M. J., Hopkins, K. L., Ellaby, N., Randall, L., Lemma, F., et al. Detection in livestock of the human pandemic Escherichia coli ST131 fimH30(R) clone carrying blaCTX-M-27. J. Antimicrob. Chemother. 2021; 76, 263–265.
Duggett, N., Abuoun, M., Randall, L., Horton, R., Lemma, F., Rogers, J., et al. The importance of using whole genome sequencing and extended spectrum beta-lactamase selective media when monitoring antimicrobial resistance. Sci. Rep. 2020; 10, 19880.
Hassuna NA, Khairalla AS, Farahat EM, Hammad AM, Abdel-Fattah M. Molecular characterization of Extended-spectrum β lactamase- producing E. coli recovered from community-acquired urinary tract infections in Upper Egypt. Sci Rep. 2020; 10(1):2772.
Day, M. J., Hopkins, K. L., Wareham, D. W., Toleman, M. A., Elviss, N., Randall, L., et al. Extended-spectrum β-lactamase-producing Escherichia coli in humanderived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study. Lancet Infect. Dis. 2019; 19, 1325–1335.
Bush K, Jacoby GA. Updated functional classification of b-lactamases. Antimicrob Agents Chemother 2010; 54: 969–76.
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 34th ed.; CLSI supplement M100; CLSI: Wayne, PA, USA, 2023.
Jayanti Jena et al. Prevalence of TEM, SHV, and CTX-M genes of extendedspectrum b-lactamase-producing Escherichia coli strains isolated from urinary tract infections in adults. 3 Biotech. 2017; 7:244.
Goyal A, Prasad KN, Prasad A, Gupta S, Ghoshal U, Ayyagiri A. Extended spectrum β-lactamases in Escherichia coli & Klebsiella pneumonia & associated risk factors. Indian J Med Res. 2009; 129:695 700.
Geser, N., Stephan, R. and Hächler, H. Occurrence and Characteristics of Extended-Spectrum β-Lactamase (ESBL) Producing Enterobacteriaceae in Food Producing Animals, Minced Meat and Raw Milk. BMC Veterinary Research. 2012; 8, 21.
Kaur M, Aggarwal A. Occurence of the CTX-M, SHV and the TEM genes among the extended spectrum β-lactamase producing isolates of Enterobacteriaceae in a tertiary care hospital of North India. J Clin Diagn Res. 2013; 7(4):642-645.
Alipourfard I, Nili NY. Antibiogram of extended spectrum beta lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae isolated from hospital samples. Bangladesh J Med Microbiol. 2011; 4(1): 32-36.
Jabeen K, Zafar A, Hasan R. Frequency and sensitivity pattern of extended-spectrum β-lactamase producing isolates in a tertiary care hospital laboratory of Pakistan. J Pak Med Assoc. 2005; 55(10): 436-439.
Sharma M, Pathak S, Srivastava P. Prevalence and antibiogram of extended spectrum β-lactamase (ESBL) producing gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp. J Clin Diagn Res. 2013; 7(10):2173–2177.
Umadevi S, Kandhakumari G, Joseph NM, Kumar S. Prevalance and antimicrobial susceptibility pattern of ESBL producing gram negative bacilli. Journal of Clinicaland Diagnostic Research. 2011; 5(2):236 239.
Padmini S, Raju B, Mani KR. Detection of Enterobacteriaceae producing CTX-M extended spectrum β-lactamases from a tertiary care hospital in South India. Indian Journal of Medical Microbiology. 2008; 26(2):163-6.
Heikki Ilmavirta et al. Increasing proportions of extended-spectrum β-lactamase-producing isolates among Escherichia coli from urine and bloodstream infections: results from a nationwide surveillance network, Finland, 2008 to 2019. Euro Surveill. 2023; 28(43):2200934.
Kaye KS, Gupta V, Mulgirigama A, Joshi AV, Scangarella-Oman NE, Yu K, et al. Antimicrobial Resistance Trends in Urine Escherichia coli Isolates From Adult and Adolescent Females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management. Clin Infect Dis. 2021; 73(11):1992-9.
M.C. El bouamri et al. Molecular characterization of extended spectrum β-lactamase-producing Escherichia coli in a university hospital in Morocco, North Africa. African Journal of Urology. 2015; 21(3) : 161-166.
Katja Hrovat et al. Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolated from lower respiratory tract samples between 2002 and 2019 in the Central Slovenia region. Annals of Clinical Microbiology and Antimicrobials. 2024; 23 (6).
Sheetal Verma et al. olecular Characterization of Extended Spectrum β-Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates and Their Antibiotic Resistance Profile in Health Care-Associated Urinary Tract Infections in North India. J Lab Physician. 2022; 15(2):194–201
Borah V V, Saikia K K, Chandra P, Hazarika N K, Chakravarty R. New Delhi metallo-β-lactamase and extended spectrum β-lactamases co-producing isolates are high in community-acquired urinary infections in Assam as detected by a novel multiplex polymerase chain reaction assay. Indian J Med Microbiol. 2016; 34(02):173–182.
Sumontha Chaisaeng et al. High prevalence of ESBL-producing E. coli phylogroup B2 clinical isolates in northeastern Thailand. BMC Microbiology. 2024; volume 24, Article number: 425 .
Ahmad Hamad Pishtiwan et al. Prevalence of blaTEM, blaSHV, and blaCTX-M Genes among ESBL-Producing Klebsiella pneumoniae and Escherichia coli Isolated from Thalassemia Patients in Erbil, Iraq. Mediterr J Hematol Infect Dis. 2019 ;11(1):e2019041.
Govindaswamy A, Bajpai V, Khurana S. Prevalence and characterization of beta-lactamase-producing Escherichia coli isolates from a tertiary care hospital in India . J Lab Physicians. 2019; 11(02):123–127.
Castanheira M, Simner PJ, Bradford PA. Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection. JAC Antimicrob Resist. 2021; 3(3):dlab092.
Kim B, Kim JH, Lee Y. Virulence factors associated with Escherichia coli bacteremia and urinary tract infection. Ann Lab Med. 2022; 42(2):203–12.'
Jena J, Sahoo R K, Debata N K, Subudhi E. Prevalence of TEM, SHV, and CTX-M genes of extended-spectrum β-lactamase-producing Escherichia coli strains isolated from urinary tract infections in adults. 3 Biotech. 2017; 7(04):244.
Tsang et al. Diversity, functional classification and genotyping of SHV β-lactamases in Klebsiella pneumoniae. BioRvix. 2024.
Rajivgandhi G, Maruthupandy M, Manoharan N. Detection of TEM and CTX-M genes from ciprofloxacin resistant Proteus mirabilis and Escherichia coli isolated on urinary tract infections (UTIs) Microb Pathog. 2018;121:123–130.
Sarin Kamboj et al. Prevalence and Risk Factors of β-Lactamase Genes of Extended-Spectrum β-Lactamases-Producing Escherichia coli From Dairy Farm Environments of Haryana, India. Environ Health Insights. 2024 Oct 31:18:11786302241296694
Ahmed Gomaa Ahmed Elsayed et al. Prevalence of extended-spectrum beta-lactamase and molecular detection of blaTEM, blaSHV, and blaCTX-M genotypes among gram-negative Bacilli isolates from hospital acquired infections in pediatrics, one institutional study. Ital J Pediatr. 2024 ;50:31.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
